- Physicians Demonstrate Utility of New Tool for Cardiovascular and
Endovascular Specialists in Live Case Studies -
VANCOUVER, Sept. 16 /CNW/ - Neovasc Inc. (TSXV: NVC), a new specialty
vascular device company comprised of the former Medical Ventures Corp.,
Neovasc Medical Ltd. and B-Balloon Ltd., today reported that leading
physicians support expanding use of its Metricath(R) intravascular measurement
device. Metricath is an arterial and in-stent measurement system that provides
precise diameter and cross-sectional area measurements to aid in stent size
selection and optimization. This unique tool was highlighted during the New
Cardiovascular Horizons conference, the fourth largest cardiovascular
conference in the nation.
Metricath was used during several live cases presented via satellite to
conference attendees and was also highlighted during a symposium presentation
by Dr. Raed Aqel, Director of Interventional Cardiology at VA Birmingham, UAB
General and Interventional Faculty. Physicians attending these events reported
that they were "impressed" with Metricath's speed and precision.
"Typically cardiovascular and endovascular physicians think they're
pretty good at measuring vessels but we're often off by a significant amount,"
explained New Cardiovascular Horizons Co-Chairmen Dr. David Allie and Dr.
Craig Walker during the live cases. "Metricath is a new tool that enables us
to quickly and precisely take intravascular measurements without guesswork.
Now I can look at accurate vessel sizing and tailor my therapy. This is
changing the way we treat vessels and allows treatment to be more precise and
The conference brings together a wide range of physicians including
interventional cardiologists, cardiac and vascular surgeons, interventional
radiologists and cath lab technologists. The presentations highlighted the
expanding use of Metricath to peripheral vascular applications.
Dr. Allie added, "Cardiologists have been treating coronary arteries with
high precision for years and it's time we do the same in the peripheral
The potential utility of Metricath in improving the accuracy of stent
expansion was highlighted in the symposium presentation by Dr. Aqel that
concluded, "In 90% of the renal interventions that I studied, which appeared
acceptable based on angiography, Metricath revealed these stents were
significantly under-deployed and required adjunct treatment based on the
Metricath findings." Dr. Aqel's study, "Prevalence of Renal Artery Stenosis
and the Use of a 3-Dimensional Balloon Catheter to Identify Underdeployed
Stents" was also reported in the June 2008 issue of the Journal of Invasive
The New Cardiovascular Horizons conference was held September 10-13, 2008
in New Orleans. For more information, visit www.newcvhorizons.com
About Neovasc Inc.
Neovasc Inc. (formerly Medical Ventures Corp.), is a new specialty
vascular device company that develops, manufactures and markets medical
devices for the rapidly growing vascular and surgical marketplace. Neovasc is
comprised of the former Medical Ventures, Neovasc Medical Ltd. and B-Balloon
Ltd. The company's current products include, Metricath(R) for intravascular
measurement and PeriPatch(TM) surgical tissue and staple line reinforcement
products. Neovasc has a development pipeline of innovative new products, and
provides contract medical device development and manufacturing services. For
more information, visit: www.neovasc.com.
Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words
"anticipates," "believes," "may," "continues," "estimates," "expects," and
"will" and words of similar import, constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, among others, the following: general economic and business
conditions, both nationally and in the regions in which the Company operates;
history of losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product candidates,
ability to properly integrate newly acquired businesses, technology changes;
competition; changes in business strategy or development plans; the ability to
attract and retain qualified personnel; existing governmental regulations and
changes in, or the failure to comply with, governmental regulations; liability
and other claims asserted against the Company; and other factors referenced in
the Company's filings with Canadian securities regulators. Although the
Company believes that expectations conveyed by the forward-looking statements
are reasonable based on the information available to it on the date such
statements were made, no assurances can be given as to the future results,
approvals or achievements. Given these uncertainties, readers are cautioned
not to place undue reliance on such forward-looking statements. The Company
does not assume the obligation to update any forward-looking statements except
as otherwise required by applicable law.
For further information:
For further information: Corporate contact: Neovasc Inc., Cynthia Roney,
(604) 916-6541; U.S. media and investor contact: GendeLLindheim BioCom
Partners, Barbara Lindheim, (212) 918-4650